腹腔镜辅助与开腹远端胃切除术治疗局部进展期胃癌的5年生存结局:JLSSG0901随机临床试验
该多中心、开放标签、非劣效性随机试验纳入502例局部进展期胃癌患者,比较腹腔镜辅助远端胃切除术(LADG)与开腹远端胃切除术(ODG)联合D2淋巴结清扫的5年生存结局。结果显示LADG的5年无复发生存率非劣效于ODG,总生存无显著差异,严重术后并发症两组相似。
要点
- LADG联合D2清扫的5年无复发生存非劣效于ODG(HR 0.96,90%CI 0.72-1.26)。
核心结论
- 由合格外科医生实施的LADG联合D2淋巴结清扫治疗局部进展期胃癌,基于5年随访数据非劣效于ODG。
- 腹腔镜入路可能成为局部进展期胃癌的标准治疗。
研究设计与样本
- 多中心、开放标签、非劣效性、前瞻性随机临床试验,在日本37家机构开展。
- 2009年11月26日至2016年7月29日纳入组织学证实为胃癌的合格患者,按1:1随机分配至ODG组或LADG组。
- 全分析集共502例:ODG组254例(50.6%),LADG组248例(49.4%)。
- 主要终点为5年无复发生存,风险比非劣效界值设为1.31。
主要发现
- ODG组5年无复发生存率为73.9%(95%CI 68.7%-79.5%),LADG组为75.7%(95%CI 70.5%-81.2%)。
- 两组复发模式相似。
临床怎么用
- 对于局部进展期胃癌,在合格外科医生操作下,可考虑将LADG联合D2淋巴结清扫作为ODG的替代选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Evidence of implementation of laparoscopic gastrectomy for locally advanced gastric cancer is currently insufficient, as the primary end point in previous prospective studies was evaluated at a median follow-up time of 3 years. More robust evidence is necessary to verify noninferiority of laparoscopic gastrectomy. OBJECTIVE: To compare 5-year survival outcomes between laparoscopy-assisted distal gastrectomy (LADG) and open distal gastrectomy (ODG) with D2 lymph node dissection for locally advanced gastric cancer. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter, open-label, noninferiority, prospective randomized clinical trial. Between November 26, 2009, and July 29, 2016, eligible patients with histologically proven gastric carcinoma from 37 institutes in Japan were enrolled. Two interim analyses and final analysis were performed in October 2014, May 2018, and November 2021, respectively. INTERVENTIONS: Patients were randomly assigned (1:1) to either the ODG or LADG group. The procedures were performed exclusively by qualified surgeons. MAIN OUTCOMES AND MEASURES: The primary end point was 5-year relapse-free survival, and the noninferiority margin for the hazard ratio (HR) was set at 1.31. The secondary end points were 5-year overall survival and safety. RESULTS: A total of 502 patients were included in the full-analysis set: 254 (50.6%) in the ODG group and 248 (49.4%) in the LADG group. Patients in the ODG group had a median (IQR) age of 67 (33-80) years and included 168 males (66.1%). Patients in the LADG group had a median (IQR) age of 64 (34-80) years and included 169 males (68.1%). No significant differences were observed in severe postoperative complications between the 2 groups in the safety analysis (ODG, 4.7% [11 of 233] vs LADG, 3.5% [8 of 227]; P = .64). The median (IQR) follow-up for all patients after randomization was 67.9 (60.3-92.0) months. The 5-year relapse-free survival was 73.9% (95% CI, 68.7%-79.5%) and 75.7% (95% CI, 70.5%-81.2%) for the ODG and LADG groups, respectively, and the HR was 0.96 (90% CI, 0.72-1.26; noninferiority 1-sided P = .03). Further, no significant difference was observed in overall survival time between the 2 groups, and the HR was 0.83 (95% CI, 0.57-1.21; P = .34). The pattern of recurrence was similar between the 2 groups. CONCLUSIONS AND RELEVANCE: Results of this study show that on the basis of 5-year follow-up data, LADG with D2 lymph node dissection for locally advanced gastric cancer, when performed by qualified surgeons, was proved noninferior to ODG. This laparoscopic approach could become a standard treatment for locally advanced gastric cancer. TRIAL REGISTRATION: UMIN Clinical Trial Registry: UMIN000003420.
引用
- Etoh T, Ohyama T, Sakuramoto S, et al. Five-Year Survival Outcomes of Laparoscopy-Assisted vs Open Distal Gastrectomy for Advanced Gastric Cancer: The JLSSG0901 Randomized Clinical Trial. JAMA Surg. 2023. PMID: 36920382. doi:10.1001/jamasurg.2023.0096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。